Clinical Trials Browser

Withdrawn × Primary Myelofibrosis × durvalumab × Clear all

NCT02871323 2019-08-20

Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis

Phase 1 Withdrawn

Polycythemia Vera, Primary Myelofibrosis